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Abstract
Efficient recruitment and activation of immuno-com-
petent cells is crucial for an effective immune response
to hepatitis C virus (HCV) infection. Chemokines and
chemokine receptors have been shown to be critically
involved in these processes. 
The CCR5 chemokine receptor is expressed on sev-
eral cells of the immune system and has been suggest-
ed to influence the susceptibility to HCV infection as
well as natural course and progression of hepatitis C.
However, these reports are still controversial.
This review will summarize and discuss the avail-
able data regarding the potential role of CCR5 and its
ligands in hepatitis C.
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CHEMokInEs anD CHEMokInE RECEPToRs
Chemokines, a group of chemotactic cytokines exert
chemotactic  and  immunoregulatory  actions  [1].  fur-
thermore, these molecules are involved in modulation
of  adhesion  processes  at  the  endothelium  and  thus
promote the transendothelial migration of leukocytes
(haptotaxis). In addition, some chemokines stimulate
angiogenesis or angiostasis and thus may play a further
role in the suppression of tumor growth or the estab-
lishment of an inflammatory response.
Currently,  about  50  human  chemokines  and  20
chemokine receptors have been described. Traditional-
ly,  chemokines  and  chemokine  receptors  have  been
classified into four families (CXC, CC, C and CX3C).
several years ago, a new nomenclature was intro-
duced in which each ligand and each receptor is identi-
fied as a member of a sub-family and carries a special
number  [2].  for  example,  a  chemokine  designated
CCl5  is  a  member  of  the  CC  sub-family  with  the
number  5.  This  special  chemokine  was  formerly
known as RanTEs.
Despite their essential importance for the immune
system  chemokines  and  chemokine  receptors  have
been associated with an extraordinary number of dis-
eases [3]. These include autoimmune diseases [4, 5],
cancer [5], lung [3], and vascular diseases [6] as well as
transplant rejection [7-10]. 
In  addition,  the  human  immunodeficiency  virus
(HIV) uses different chemokine receptors as co-recep-
tors for entry into the cell [11].
CC  chemokines  are  an  important  subset  of
chemokines. They activate specific inflammatory cells
such as monocytes or T lymphocytes and recruit them
to  the  site  of  inflammation.  These  CC  chemokines
bind to specific G protein-coupled receptors, thereby
initiating activation and migration of cells.
The CC chemokines CCl3 (MIP-1a), CCl4 (MIP-
1b), CCl5 (RanTEs), and CCl3l1 are the natural
ligands  of  the  CC-chemokine  receptor  CCR5  (CC-
CkR5, ChemR13 or CMkBR5). The coding sequence
for this receptor is located at position 21 on the short
arm of chromosome 3 and has a coding sequence of
1056 base pairs, which is translated into a protein of
352 amino acid length.
EXPREssIon of CHEMokInE RECEPToRs
Based on their cytokine profile CD4-positive T-cells
can be divided into different subclasses: TH1 cells (T
helper cells type 1) secrete Il-2, Ifn-g and lympho-
toxin,  whereas  TH2  cells  produce  Il-4,  Il-5,  Il-6, 
Il-9,  Il-10,  and  Il-13.  TH1  cells  primarily  control
the  cellular  immune  response  and  appear  to  be  in-
volved in chronic inflammatory processes. Th2 cells
support the formation of specific antibodies by in-
creasing the B-cell proliferation and their differentia-
tion into plasma cells and play an important role in
the development of allergic reactions due to the pro-
motion of IgE production. Interestingly, the expres-
sion of specific chemokine receptors is closely associ-
ated with the differentiation and activation of specific
inflammatory  cells.  Thus,  the  CCR5  receptor  is  ex-
pressed on TH1 lymphocytes [12] but not on TH2
lymphocytes,  which  primarily  express  CCR3,  and
CCR8 and CCR4.
Beyond TH1 cells, CCR5 has also been detected on
monocytes,  memory  T  cells  (CD45Ro),  stem  cells,
dendritic cells, microglia, and on a main group of cy-
totoxic CD8 (+) T lymphocytes.
HCV anD CCR5
Infiltration  of  mononuclear  inflammatory  cells  is  a
central feature of hepatitis C virus (HCV) infection.
Here, many of the liver-infiltrating cells express high
levels of the CCR5 receptor. Moreover, high levels of
the chemokines CCl3, CCl4 and CCl5 can be found
in the HCV-infected liver [13]. 
In vitro data suggest that the hepatitis C virus can
directly influence the secretion of these chemokines.
for instance, it could be shown that binding of the
HCV E2 envelope protein to the tetraspanin CD81,
which serves as a co-receptor for HCV, induces release
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addition, the HCV core and ns5a proteins have been
demonstrated to affect CCl5 secretion by modulating
CCl5 promoter activity [15].
of note, CCR5 has been shown to promote hepatic
fibrosis in mice and marked up-regulation of CCl5
and CCR5 has been found in patients with hepatic cir-
rhosis,  confirming  activation  of  the  CC  chemokine
system in human fibrogenesis [16, 17]. 
In  contrast  to  the  infected  liver  significantly  re-
duced numbers of CCR5-expressing lymphocytes can
be found in the peripheral blood of HCV-infected pa-
tients. This may be due to HCV-induced intrahepatic
chemokine  secretion  mediating  the  hepatic  recruit-
ment of CCR5-mediated hepatic (+) T-cell and thus
reflect altered compartmentalization of CCR5(+) lym-
phocytes.  
a strong anti-viral type 1 immune response has been
shown to be associated with a successful elimination of
the virus, both during the acute phase of infection and
an antiviral therapy [18-20]. This would suggest that
accumulation of CCR5 (+) TH1 cells in the HCV-in-
fected liver contributes to an effective antiviral immune
response.  However,  these  relationships  appear  to  be
more  complex.  We  recently  showed  that  CCR5  (+)
lymphocytes are characterized by a high expression of
the inhibitory nk cell receptor nkG2a [21]. There-
fore, these cells are very sensitive to nkG2a-mediated
inhibition of cytotoxic function. as hepatitis C is asso-
ciated  with  a  high  intrahepatic  expression  of  the
nkG2a ligand Hla-E, intra-hepatic accumulation of
CCR5(+)nkG2a(+) lymphocytes could interfere with
an effective immune response. In addition, CCR5 (+)
T cells may have a role in immune-mediated liver cell
damage during chronic hepatitis C [22].
THE CCR5D32 PolyMoRPHIsM
The CCR5 gene is subject to various mutations, in-
cluding a deletion of 32 base pairs.  This mutation,
called CCR5D32, leads to a shift in the reading frame,
resulting in the formation of a truncated, non-func-
tional protein, which is not expressed on the cell sur-
face [23, 24]. In a Caucasian population the CCR5D32
allele frequency is about 10-20% [23].
The frequency of the CCR5D32-polymorphism de-
creases  from  northern  to  southern  Europe.  More-
over, the D32 allele is absent in african and asian co-
horts. Thus, it is believed that this mutation first oc-
curred in northern Europe not so long ago.
Individuals who are homozygous for the mutation
and  thus  "genetically  negative"  for  CCR5,  develop
normal  and  are  healthy.  The  same  was  observed  in
CCR5 knockout mice. Therefore, it was originally pre-
sumed that the CCR5 receptor has no relevant impor-
tance to the immune system. In further studies, how-
ever, it could be shown that lack of CCR5 is associat-
ed  with  a  significantly  altered  immune  response  in
mice. for example, infection with Cryptpcoccus neo-
formans is often fatal in CCR5-deficient mice, whereas
wild-type mice survive. furthermore, experiments us-
ing CCR5 knockout demonstrated that lack of CCR5
is associated with an increased T-cell immune response
in various infectious diseases [25-27].
Even  in  non-infectious  inflammatory  reactions
CCR5 seems to play an important role in the regula-
tion of T-cell functions. Recently, it has been reported
that CCR5-deficient mice, in which a T cell-mediated
autoimmune hepatitis had been induced, displayed a
significantly  greater  liver  damage  in  comparison  to
CCR5-positive mice [28].
studies on the clinical relevance of CCR5D32 muta-
tion in humans indicated that absence of the CCR5 re-
ceptor may, under certain circumstances, have either a
positive or a negative effect. Patients carrying a ho-
mozygous  CCR5D32-genotype  have  a  higher  risk  of
death during infection with West nile virus [29]. on
the  other  hand,  it  is  presumed  that  the  absence  of
CCR5 confers some protection against infection with
smallpox (or the plague), which is reflected by the rela-
tively high prevalence of this mutation in Central and
northern Europe.
Moreover, CCR5 has been suggested to play a role
in  transplant  rejection  [7-10,  30].  for  instance,  a
prospective,  biopsy-controlled  study  suggested  that
the  local  expression  of  the  CCR5-ligand  RanTEs
(CCl5) leads to the directional movement of activated
CCR5 bearing T cells into the renal allograft thereby
mediating  acute  rejection  [10].  fischrieder  et  al.  re-
ported  patients  homozygous  for  CCR5D32 to  show
longer  survival  of  renal  transplants  than  those  with
other genotypes [9]. In contrast, Bickerstaff and co-
workers  found  rapid  rejection  of  renal  allografts  in
CCR5–/–  mice  with  many  histopathologic  features
observed during aHR of human renal allografts [8].
Thus, the exact role of CCR5/CCR5 polymorhpisms
in renal transplantation remains controversial [30].
HCV anD CCR5D32
With respect to HCV infection data regarding the im-
portance  of  CCR5D32  mutation  are  conflicting.
Woitas et al. reported that patients with chronic HCV
infection were significantly more likely to exhibit the
homozygous  CCR5-D32/CCR5-D32  genotype  com-
pared  to  a  healthy  control  group.  Moreover,  CCR5-
D32 homozygosity in this study was associated with
significantly increased HCV viral loads and CD8+ T
lymphocyte counts in the peripheral blood [31]. Thus,
the results of this study would suggest that individuals
with  a  CCR5D32/CCR5D32  genotype  display  an  in-
creased susceptibility to HCV infection.
However,  in  subsequent  studies  this  association
could not be confirmed. In this regard, it has been
speculated that increased CCR5D32-frequency may be
a specific characteristic of haemophilic patients with
chronic hepatitis C but without HIV infection - and
rather reflects resistance to HIV-1 than increased sus-
ceptibility  to  HCV.  However,  a  detailed  statistical
analysis showed that the high frequency of CCR5D32
in chronic hepatitis C reported by Woitas et al. could
not be explained by the HIV-mediated selection pres-
sure alone [32].
alternatively, the strategy of patient selection in the
Woitas study (haemophilia versus chronic liver disease)
or the analysis of heterogeneous cohorts (stage and
duration of infection, infecting HCV genotype, demo-
graphic factors) might explain these discrepant results.
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mogeneous cohorts of HCV-infected women with a
known  source  of  infection.  In  the  late  70s  these
women  were  infected  by  anti-D  immunoglobulin 
contaminated with hepatitis C virus (HCV) genotype
1b  from  a  single  erythrocyte  donor  administered 
for prophylaxis of rhesus isoimmunization through-
out  East  Germany  and  Ireland,  respectively.  In 
contrast to the data published by Woitas and co-work-
ers  the  CCR5D32 mutation  was  associated  with 
spontaneous  elimination  of  the  virus  in  the  Irish 
anti-D cohort [33]. However, in the Eastern German
"anti-D cohort," we found carriers of the CCR5D32
polymorphism to be significantly more likely to devel-
op  chronic  infection  than  women  with  a  homoge-
neous wild-type genotype (nattermann et al., aaslD
2009).
similar discrepant results have been published re-
garding a possible association between the CCR5D32
polymorphism and the degree of the HCV-associated
hepatitis. Data obtained in the Irish “anti-D cohort”
[33] and in two other studies [34, 35] showed a less
pronounced  hepatic  inflammation  in  carriers  of  the
CCR5D32 mutation  as  compared  to  patients  with  a
homozygous wild type. However, these results could
not be confirmed in other publications [36-38].
In contrast to these controversial data, it is widely
accepted that the CCR5D32 mutation does not affect
response to standard combination therapy with pegy-
lated interferon and ribavirin. although the CCR5D32
polymorphism  was  associated  with  a  significantly
poorer response to monotherapy with standard inter-
feron [39], no study could confirm a similar effect for
patients treated with pegylated interferon in combina-
tion with ribavirin [32, 39, 40].
Recently, Dolan et al. published a very elgant and
comprehensive study which might provide some ex-
planations regarding the controversial data on the role
of CCR5 in hepatitis C as this work shed light on the
complexity of such associations [41]. In this study dif-
ferent cohorts of HIV-positive and HIV–negative per-
sons were analyzed with regard to polymorphisms in
the  CCR5  gene  and  the  gene  of  the  CCR5  ligand
CCl3l1. CCR5 is an important co-receptor for HIV
and  earlier  studies  demonstrated  that  the  CCR5D32
mutation blocks infection of CD4 lymphocytes. Dolan
et al. identified another mechanism by which CCR5 in
association with its ligands affect the course of HIV
infection. 
In this work the study subjects were classified into
three 'genetic risk groups' (GRGs) based on variation
in CCR5-CCl3l1 genotypes that are associated with
risk of acquiring HIV infection and on HIV replication. 
Interestingly the authors could show a direct associ-
ation of these GRks with the cell-mediated immune
response. as a marker they determined the delayed-
type immune response (type IV), which is a common
'readout' of cellular immunity. This immune reaction is
based on activation of TH1 lymphocytes induced by a
soluble antigen which in turn results in activation of
macrophages. a typical example is the tuberculine test
which induces an immune reaction of pre-sensitized
T-lymphocytes  after  inoculation  of  tuberculine  into
the skin. Dolan and co-workers showed an increased
type-IV immune response in those GRGs associated
with a delayed disease progression. 
Thus, the authors concluded that CCR5 and its lig-
ands not only interfere with viral entry of HIV into
the cell but also affect anti-viral responses via modu-
lating cellular immunity. 
The complexity of these associations was further
emphasized by the observation that the CCR5 haplo-
type (HHG*2) comprising the D32-mutation (both ho-
mozygous  or  in  combination  with  another  specific
haplotype (HHE)) is a predictor of a weak cell-mediat-
ed immune response and a rapid progression of HIV
infection.  However,  the  same  CCR5  HHG*2  haplo-
type in combination with the CCR5 HHC haplotype
was associated with a slower progression of infection
and possibly with a stronger immune response.
similar complex relationships could also play a role
in  HCV  infection.  for  instance,  variations  of  the
CCl3l1  gene  have  recently  been  shown  to  affect
HCV infection [42]. Moreover, ahlenstiehl et al. could
show a significantly decreased HCV-specific Ifn-g re-
sponse of CD8(+) T-cells in carriers of the CCR5D32
allele as compared to cells from patients with a ho-
mozygeous wildtype genotype. This finding suggests
the CCR5D32 polymorphisms to possibly affect cellu-
lar immune responses in HCV infection [43].
In summary there is clear evidence for a critical role
of the CCR5 receptor and itsﾴ ligands for the regula-
tion of immune response which might also play a role
in HCV infection. However, further studies with larger
number of patients and a more detailed genetic analy-
sis are necessary to precisely define the role of CCR5
in HCV infection.
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